{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T19:31:50Z","timestamp":1777923110367,"version":"3.51.4"},"reference-count":22,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Microbial Drug Resistance"],"published-print":{"date-parts":[[2022,4,1]]},"abstract":"<jats:p>\n                    Infections due to extended-spectrum \u03b2-lactamase (ESBL)\u2013producing Enterobacterales are an increasingly common problem. For many of these infections, no oral treatment options are available. The activity of amoxicillin\u2013clavulanate combined with ceftibuten or cefpodoxime was evaluated against a group of\n                    <jats:italic toggle=\"yes\">Escherichia coli<\/jats:italic>\n                    and\n                    <jats:italic toggle=\"yes\">Klebsiella pneumoniae<\/jats:italic>\n                    clinical isolates possessing a variety of CTX-M- and SHV-type ESBLs; some possessed bla\n                    <jats:sub>TEM1<\/jats:sub>\n                    as well. In time-kill studies, the combination of subinhibitory concentrations of amoxicillin\u2013clavulanate with ceftibuten was bactericidal and synergistic for all strains with an amoxicillin\u2013clavulanate MIC \u226432\u2009\u03bcg\/mL, regardless of the type of ESBL and the cephalosporin minimal inhibitory concentration (MIC). The combination with cefpodoxime was also bactericidal and synergistic against all but one of these strains. These combinations were further tested against two strains of\n                    <jats:italic toggle=\"yes\">K. pneumoniae<\/jats:italic>\n                    and one\n                    <jats:italic toggle=\"yes\">E. coli<\/jats:italic>\n                    in a sepsis model using\n                    <jats:italic toggle=\"yes\">Galleria mellonella<\/jats:italic>\n                    larvae. The combination of amoxicillin\u2013clavulanate with ceftibuten demonstrated a synergistic survival benefit against all three strains. The combination with cefpodoxime also improved survival against the two\n                    <jats:italic toggle=\"yes\">K. pneumoniae<\/jats:italic>\n                    strains, but not the\n                    <jats:italic toggle=\"yes\">E. coli<\/jats:italic>\n                    strain. These findings support combining amoxicillin\u2013clavulanate with ceftibuten, and possibly cefpodoxime, for the treatment of infections due to ESBL producers and suggest that having an amoxicillin\u2013clavulanate MIC of 32\u2009\u03bcg\/mL or less may predict activity at clinically achievable concentrations. Clinical studies are warranted to further evaluate this therapeutic approach.\n                  <\/jats:p>","DOI":"10.1089\/mdr.2021.0025","type":"journal-article","created":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T10:39:23Z","timestamp":1650623963000},"page":"419-424","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["<i>In Vitro<\/i>\n                    and\n                    <i>In Vivo<\/i>\n                    Activity of Amoxicillin\u2013Clavulanate Combined with Ceftibuten or Cefpodoxime Against Extended-Spectrum \u03b2-Lactamase\u2013Producing\n                    <i>Escherichia coli<\/i>\n                    and\n                    <i>Klebsiella pneumoniae<\/i>"],"prefix":"10.1177","volume":"28","author":[{"given":"Aanchal","family":"Gupta","sequence":"first","affiliation":[{"name":"Infectious Diseases Division, SUNY Downstate Medical Center, Brooklyn, New York, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saquib","family":"Malik","sequence":"additional","affiliation":[{"name":"Infectious Diseases Division, SUNY Downstate Medical Center, Brooklyn, New York, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Kaminski","sequence":"additional","affiliation":[{"name":"Infectious Diseases Division, SUNY Downstate Medical Center, Brooklyn, New York, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Landman","sequence":"additional","affiliation":[{"name":"Infectious Diseases Division, SUNY Downstate Medical Center, Brooklyn, New York, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6043-4298","authenticated-orcid":false,"given":"John M.","family":"Quale","sequence":"additional","affiliation":[{"name":"Infectious Diseases Division, SUNY Downstate Medical Center, Brooklyn, New York, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2022,4,18]]},"reference":[{"key":"e_1_3_6_2_2","unstructured":"Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States 2019 (2019 AR Threats Report). CDC Atlanta GA. Available at www.cdc.gov\/DrugResistance\/Biggest-Threats.html#extend."},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0220265"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2020.10.020"},{"issue":"1","key":"e_1_3_6_5_2","first-page":"198","article-title":"Other antimicrobials of interest in the era of extended-spectrum \u03b2-lactamases: fosfomycin, nitrofurantoin and tigecycline","volume":"14","author":"Garau J.","year":"2009","unstructured":"Garau J. 2009. Other antimicrobials of interest in the era of extended-spectrum \u03b2-lactamases: fosfomycin, nitrofurantoin and tigecycline. Clin. Microbiol. Infect. 14,(Suppl 1)::198\u2013202.","journal-title":"Clin. Microbiol. Infect"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-017-0150-5"},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2018.08.010"},{"key":"e_1_3_6_8_2","first-page":"1897","volume-title":"Arch. Intern. Med","author":"Rodriguez-Bano J.","year":"2008","unstructured":"Rodriguez-Bano J., , Alcala J.C, , Cisneros J., et al. 2008. Community infections caused by extended-spectrum \u03b2-lactamase-producing Escherichia coli. Arch. Intern. Med. 168:1897\u20131902."},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa034"},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa126"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz519"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00037-09"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa183"},{"key":"e_1_3_6_14_2","first-page":"2021","volume":"37","author":"Cohen Stuart J.","year":"2018","unstructured":"Cohen Stuart J., , Leverstein-Van Hall M., , Kortmann W., et al. 2018. Ceftibuten plus amoxicillin-clavulanic acid for oral treatment of urinary tract infections with ESBL-producing E. coli and K. pneumoniae: a retrospective observational case-series. Eur. J. Clin. Microbiol. Infect. Dis. 37:2021\u20132025.","journal-title":"Ceftibuten plus amoxicillin-clavulanic acid for oral treatment of urinary tract infections with ESBL-producing E. coli and K. pneumoniae: a retrospective observational case-series. Eur. J. Clin. Microbiol. Infect. Dis"},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2019.0065"},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e318271f369"},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky322"},{"key":"e_1_3_6_18_2","unstructured":"Clinical and Laboratory Standards Institute. 2017. Performance standards for antimicrobial susceptibility testing. 27th ed. CLSI supplement M100. Clinical and Laboratory Standards Institute Wayne PA."},{"key":"e_1_3_6_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks063"},{"key":"e_1_3_6_20_2","doi-asserted-by":"publisher","DOI":"10.1086\/421495"},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx419"},{"key":"e_1_3_6_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00526-12"},{"key":"e_1_3_6_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.06248-11"}],"container-title":["Microbial Drug Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/mdr.2021.0025","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2021.0025","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2021.0025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T20:39:21Z","timestamp":1777667961000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/mdr.2021.0025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,1]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4,1]]}},"alternative-id":["10.1089\/mdr.2021.0025"],"URL":"https:\/\/doi.org\/10.1089\/mdr.2021.0025","relation":{},"ISSN":["1076-6294","1931-8448"],"issn-type":[{"value":"1076-6294","type":"print"},{"value":"1931-8448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,1]]}}}